Skip to content
MarketScale
‹ Back to IndustriesHealthcare

DESIGN TRANSFER: A PROCESS NOT A SINGULAR EVENT

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process.

During the product development process, the Research and Development (R&D) team is under a tight deadline. They may not have the necessary resources or take sufficient time to create proper documentation. Team members may need to make decisions quickly without fully considering how they could take proactive steps to ensure design transfer will go more smoothly. Subject matter experts on the team may only focus on critical design decisions required to make the product work, without regard for manufacturing. Let’s take a look at some ways to improve design transfer.

Look at Design Transfer as a Process Rather than a Single Event

Design transfer is an integral part of the product development process, from conception through final manufacture. Highly reliable, cost-efficient medical devices require proper design transfer, and that starts with Design for Manufacturability (DFM) and Design for Manufacturing and Assembly (DFMA). In DFM and DFMA the focus is not only on the design itself, but also on the assembly method, ensuring manufacturing readiness for building Beta units, pre-production clinical units, and the pilot program. When the R&D team considers these factors and performs in-process testing, it can significantly improve product quality and reduce the overall cost of manufacturing.

Using DFMA 

The goal of DFMA is simple: to transfer product design into viable, robust production methods. To succeed, the team must establish and maintain procedures that ensure the device design translates into production specifications, including final test acceptance. The transfer should negate and/or identify remaining risks such as single-sourcing, long lead items, build timelines, and line/tooling capacity.

A Design Ready for Transfer:

  • Can be built reliably using known and proven manufacturing and assembly processes
  • Includes supporting cell/line qualifications through manufacturing validations such as Operational Qualification (OQ) and Performance Qualification (PQ)
  • Specifies and documents any inspection aids, assembly fixtures, and custom tools required for manufacture
  • Confirms completed agency testing and production target hardware meets regulatory requirements such as FDA, UL, and CE
  • Includes a complete product Bill of Material (BOM) that has been fully costed up to the customer Stock Keeping Unit (SKU) level
  • Includes packaging, labeling, and Instructions for Use (IFU)

At Sunrise Labs, we see Design Transfer as an integral process beginning early in the life of a product with many crucial steps for success. Communication between key stakeholders early and often is critical to turn innovative ideas into commercial medical devices.

Read more at sunriselabs.com

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Healthcare expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Leading with Purpose: Dr. David Foster on Faith, Healthcare Leadership, and Physician Collaboration

Dr. David Foster discusses the importance of faith in healthcare leadership and the role of physician collaboration. The conversation emphasizes how values-driven leadership can positively impact patient care. The dialogue also explores the significance of integrating personal beliefs in professional settings.

  • 01Values-driven leadership can significantly enhance patient care.
  • 02Integrating personal beliefs in professional settings can benefit healthcare leadership.
  • 03Collaboration among physicians is crucial for effective healthcare leadership.

Aug 4, 2026

Digital health VC hits $7.4B in H1 2026 as AI agents, chronic care, and workforce tools capture mega-deal capital

Digital health VC hits $7.4B in H1 2026 as AI agents, chronic care, and workforce tools capture mega-deal capital

Digital health venture funding reached $7.4B in the first half of 2026, with significant investments in AI agent platforms and chronic care tools. Mega-deals of over $100 million were a key driver of the funding surge.

  • 01Digital health VC funding hit $7.4 billion in the first half of 2026.
  • 02Mega-deals in AI agent platforms and chronic care tools exceeded $100 million.
  • 03AI, chronic care, and workforce tools dominate digital health investments.

Aug 4, 2026

Pharma M&A surges on a single day: KKR's $5.7B Integer deal, Curium's $8B Lantheus buy, and AstraZeneca's blocked megamerger signal a restructuring market

Pharma M&A surges on a single day: KKR's $5.7B Integer deal, Curium's $8B Lantheus buy, and AstraZeneca's blocked megamerger signal a restructuring market

Three significant transactions occurred in the pharmaceutical and medtech sectors on August 3, highlighting a split M&A market. While mid-market buyouts such as KKR's acquisition of Integer Holdings and Curium's purchase of Lantheus proceeded, larger megamergers like AstraZeneca's faced obstacles. This suggests a trend towards restructuring within the industry.

  • 01KKR acquired Integer Holdings for $5.7 billion.
  • 02Curium purchased Lantheus in an $8 billion deal.
  • 03AstraZeneca's megamerger attempt was blocked.

Aug 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512